Clinical Trials
24 trialsNCT05170958 2026-05-15
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT05438329 2026-05-12
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1/2 Active not recruiting
NCT06927687 2026-04-29
Study of ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Active not recruiting
NCT07512583 2026-04-06
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06057922 2026-03-12
A Study YL201 in Patients With Selected Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Active not recruiting
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT06298058 2026-01-07
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT05584800 2026-01-05
Study of ZGGS18 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT06938880 2026-01-05
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT07083323 2025-11-25
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2 Recruiting
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT06992713 2025-07-23
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT04998422 2025-03-13
A Study of HG381 Administered to Patients With Advanced Solid Tumors
HitGen Inc.
Phase 1 Recruiting
NCT06038396 2025-01-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05205850 2025-01-27
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT05414136 2024-12-24
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006
Bio-Thera Solutions
Phase 1 Completed
NCT05819684 2024-06-21
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT04638491 2024-06-10
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05877664 2024-03-06
Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Recruiting
NCT05073484 2023-10-11
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients
Bio-Thera Solutions
Phase 1 Terminated
NCT06008366 2023-09-13
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06008379 2023-09-13
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT05429398 2022-06-23
A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1 Unknown
NCT01832298 2016-12-20
Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1 Completed